The present study demonstrated that elevated IL36RN mRNA expression correlates with poorer survival outcomes in patients with GC, with validation across multiple independent datasets further reinforcing its potential as a prognostic biomarker in GC. This evidence concerns the gene IL36RN and gastric cancer.